Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Bennett is vice director of the Europain a public-private partnership which is part of the Innovative Medicines Initiative (IMI). His focus is to understand the pathophysiology of persistent pain in preclinical models. So far this has involved using next generation sequencing to fully measure transcriptional changes which occur in persistent pain states as well as trying to develop and characterise more clinically relevant animal models.